Loading patent…
AssigneeIsis Pharmaceuticals, Inc.
InventorsBrett P. Monia, C. Frank Bennett, William A. Gaarde, Trisha Lockhart, Robert McKay
Estimating the term…
Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.
A method of inhibiting the expression of hepcidin in cells or tissues comprising contacting said cells or tissues with a compound comprising a modified oligonucleotide consisting of 12 to 35 linked nucleosides and having a nucleobase sequence comprising at least 8 contiguous nucleobases complementary to an equal length portion of nucleotides 442 to 541 of SEQ ID NO:
A method comprising administering to an animal a compound comprising a modified oligonucleotide consisting of 12 to 35 linked nucleosides and having a nucleobase sequence comprising at least 8 contiguous nucleobases complementary to an equal length portion of nucleotides 442 to 541 of SEO ID NO:
A method comprising identifying a human with a disease or condition associated with hepcidin and administering to said human a therapeutically effective amount of a composition comprising a modified oligonuelcotide consisting of 12 to 35 linked nucleosides and having a nucleobase sequence comprising at least 8 contiguous nucleobases complementary to an equal length portion of nucleotides 442 to 541 of SEQ ID NO:
Dependencies are inferred from the claim text.